Breast cancer
NEW --- CDK4/6 inhibitors for everyone? First-line treatment strategies in HR+ HER2- MBCKirsten (62 years old)
Kirsten, 62 years old, was diagnosed 7 years ago with a stage III ER+ HER2- breast cancer, and received adjuvant treatment with abemaciclib for 2 years (ended 5 years ago) and letrozole for 5 years (ended 2 years ago). Due to a persistent cough, she underwent a CT scan of the thorax that revealed a suspicious lesion of the right lung.
Assessment summary:
- Postmenopausal
- Medical history: smoking (40 pack years)
- Imaging:
- 2 cm peribronchial pulmonary lesion of the right lung
- 4 suspicious lesions in bones (right scapula, sternum, spine)
- Biopsy of lung lesion: breast cancer, NST, ER 60%, PgR 10%, HER2 IHC 0, G2
- Haematology: all values normal
- Germline BRCA-status: wild type
- Somatic testing: PIK3CA wild type, ESR1 wild type